Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
This is a single institution and single-arm phase I/II study to assess the feasibility and
efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally
nonresectable ESCC.